UCB (EBR:UCB) UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development

Transparency directive : regulatory news

23/02/2021 07:03

26/02/2021 20:02
25/02/2021 07:02
23/02/2021 07:03
22/02/2021 20:02
05/02/2021 07:02
29/01/2021 20:02
22/01/2021 20:02
15/01/2021 07:02
13/01/2021 07:01
09/01/2021 20:01 ** UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and = Development ------------------------------------------------------------ =C2=B7 Through this collaboration with Microsoft, UCB seeks to discover and= develop medicines faster for people living with severe diseases in immunol= ogy and neurology =C2=B7 Microsoft will provide AI technology and applied scientists to work = alongside UCB=E2=80=99s scientists and data specialists, aiming to allow UC= B to discover new correlations and patterns critical to finding new and hig= hly individualized medicines Brussels (Belgium) and Atlanta, Ga. 23=C2=A0February 2021 =E2=80=93 7:00a (= CET) - UCB and Microsoft have announced a new multi-year, strategic collabo= ration to combine Microsoft=E2=80=99s computational services, cloud, and ar= tificial intelligence (AI) with UCB=E2=80=99s drug discovery and developmen= t capabilities. As several drug discovery activities require the analysis o= f high-dimensional data sets or multi-modal unstructured information, Micro= soft=E2=80=99s platform can support UCB=E2=80=99s scientists, including its= data scientists, to discover new medicines in a more efficient and innovat= ive way. The collaboration builds on the work UCB and Microsoft have already embarke= d on around COVID-19. As part of the COVID Moonshot project, UCB=E2=80=99s = medicinal and computational chemists contributed compound designs to this w= orldwide open-science project to create an orally bioavailable anti-viral f= or COVID-19 - with the most potent series of compounds coming from UCB desi= gns.=C2=A0 This combination of cutting-edge science, computing power, and AI algorithm= s aims to significantly accelerate the iteration cycles required to explore= a vast chemical space to test many hypotheses and identify more effective = molecules. The collaboration plans to extend this model and identify other = areas where computing power, AI, and science can accelerate the development= of life changing therapies for people living with severe diseases in immun= ology and neurology. The work will augment UCB=E2=80=99s scientists, subjec= t matter experts, and research partners across every part of the drug disco= very and delivery value chain by harnessing diverse research information an= d AI models alongside human expertise and creativity.=C2=A0 =E2=80=9CWe are delighted to be collaborating with Microsoft to uncover new= insights to better understand a patient=E2=80=99s condition, as well as th= e science, and to enable an enhanced patient experience,=E2=80=9D said Jean= -Christophe Tellier, CEO of UCB. =E2=80=9CBy amplifying the power of scient= ific innovation through digital transformation, we hope to have a better un= derstanding of what makes a patient=E2=80=99s journey unique so that we can= provide personalized and differentiated medicine in a sustainable way.=E2= =80=9D =C2=A0=C2=A0 UCB and Microsoft will explore how to combine diverse research data sets wi= th four strategic objectives in mind, allowing UCB to: =C2=B7 Improve a patient=E2=80=99s overall journey =C2=B7 Increase the impact of a treatment through a deeper understanding of= the biological causes of the disease =C2=B7 Systematically provide better research data-driven insights to enabl= e the faster discovery of therapeutic molecules =C2=B7 Accelerate clinical development timelines =E2=80=9CTogether, UCB and Microsoft are taking on some of healthcare=E2=80= =99s greatest challenges to find connected, innovative ways to create bette= r experiences, insights, and more personal and more effective care. With th= e deep knowledge that UCB offers in drug discovery and the knowledge of hum= an biology, together with Microsoft=E2=80=99s unmatched expertise in comput= er science and AI, we have a unique opportunity to reinvent the way new med= icines are created.=E2=80=9D says Jean-Philippe Courtois, EVP and President= , Microsoft Global Sales, Marketing & Operations.=C2=A0 About UCB UCB, Brussels, Belgium ( is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With more than 7 500 people in= approximately 40 countries, UCB generated revenue of =E2=82=AC 4.9 billion= in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Tw= itter: @UCB_news For further information, UCB: UCB Communications Erica Puntel Digital Business Transformation, UCB T 404.938.5359, =C2=A0=C2=A0 Laurent Schots Global Communications, UCB T: +32 (0)2 559 92 64, Investor Relations Antje Witte Investor Relations, UCB =C2=A0=C2=A0 T +32.2.559.94.14, =C2=A0=C2=A0 Isabelle Ghellynck Investor Relations, UCB T+32.2.559.9588, ### Forward looking statements =E2=80=93 UCB This press release contains forward-looking statements based on current pla= ns, estimates and beliefs of management. All statements, other than stateme= nts of historical fact, are statements that could be deemed forward-looking= statements, including estimates of revenues, operating margins, capital ex= penditures, cash, other financial information, expected legal, political, r= egulatory or clinical results and other such estimates and results. By thei= r nature, such forward-looking statements are not guarantees of future perf= ormance and are subject to risks, uncertainties and assumptions which could= cause actual results to differ materially from those that may be implied b= y such forward-looking statements contained in this press release. Importan= t factors that could result in such differences include: changes in general= economic, business and competitive conditions, the inability to obtain nec= essary regulatory approvals or to obtain them on acceptable terms, costs as= sociated with research and development, changes in the prospects for produc= ts in the pipeline or under development by UCB, effects of future judicial = decisions or governmental investigations, product liability claims, challen= ges to patent protection for products or product candidates, changes in law= s or regulations, exchange rate fluctuations, changes or uncertainties in t= ax laws or the administration of such laws and hiring and retention of its = employees.=C2=A0 UCB is providing this information as of the date of this press release and = expressly disclaims any duty to update any information contained in this pr= ess release, either to confirm the actual results or to report a change in = its expectations. There is no guarantee that new product candidates in the = pipeline will progress to product approval or that new indications for exis= ting products will be developed and approved. Products or potential product= s which are the subject of partnerships, joint ventures or licensing collab= orations may be subject to differences between the partners. Also, UCB or o= thers could discover safety, side effects or manufacturing problems with it= s products after they are marketed. Moreover, sales may be impacted by inte= rnational and domestic trends toward managed care and health care cost cont= ainment and the reimbursement policies imposed by third-party payers as wel= l as legislation affecting biopharmaceutical pricing and reimbursement. GenericFile UCB - Microsoft - Press Release - FINAL ENG ( 8595/3293570/9778125909b04b22.pdf)=0D =0D ______________________=0D If you would rather not receive future communications from UCB SA, please g= o to x6& UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=